Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non–small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and Methods: Patients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200 μg versus placebo daily for 48 months. Participation was 6 to 36 months postoperatively and required a negative mediastinal node biopsy, no excessive vitamin intake, normal liver function, negative chest x-ray, and no other evidence of recurrence. Results: The first interim analysis in October 2009, with 46% of the projected end points accumulated, showed a trend in favor of the placebo group with a low likelihood that the trial would become positive; thus, the study was stopped. One thousand seven hundred seventy-two participants were enrolled, with 1,561 patients randomly assigned. Analysis was updated in June 2011 with the maturation of 54% of the planned end points. Two hundred fifty-two SPTs (from 224 patients) developed, of which 98 (from 97 patients) were lung cancer (38.9%). Lung and overall SPT incidence were 1.62 and 3.54 per 100 person-years, respectively, for selenium versus 1.30 and 3.39 per 100 person-years, respectively, for placebo (P = .294). Five-year disease-free survival was 74.4% for selenium recipients versus 79.6% for placebo recipients. Grade 1 to 2 toxicity occurred in 31% of selenium recipients and 26% of placebo recipients, and grade ≥ 3 toxicity occurred in less than 2% of selenium recipients versus 3% of placebo recipients. Compliance was excellent. No increase in diabetes mellitus or skin cancer was detected. Conclusion: Selenium was safe but conferred no benefit over placebo in the prevention of SPT in patients with resected NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064 · cited 1×
“Defining the optimal patient population, appropriate clinical setting, risk categorization, and best tolerated and most active chemopreventive agents for lung cancer remains a challenge despite major strides in early detection of lung cancer.(35)”
Background(1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301501 · Cited by 4,737
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638 · cited 1×
“Previous attempts at primary and secondary chemoprevention with -carotene,(5) -tocopherol,(6) and several retinoids(7,8) have largely shown no benefit of these agents.(6,9) Positive outcomes for vitamin B12, 10 folic acid,(10) aspirin,(11) and the prostaglandin pathway modulators celecoxib and iloprost(12-14) have bee…”
BackgroundSelf-citationHennekens, C. H., Buring, J. E., Manson, J. E., Stampfer, M., Rosner, B., Cook, N. R., Belanger, C., LaMotte, F., Gaziano, J. M., Ridker, P. M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341801 · Cited by 2,397
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial
Duffield-Lillico, A. J. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg061 · Cited by 301 · cited 1×
“Monitoring History In 2003, the ECOG Data Monitoring Committee (DMC) reviewed the report of increased nonmelanoma skin cancer risk in patients with prior history of nonmelanoma skin cancer receiving selenium supplementation.(27) The DMC recommended modifying the protocol to indicate that all basal and squamous cell sk…”
Background
Cited by
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Davila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,184
Selenium for preventing cancer
Vinceti, M., Filippini, T., Del Giovane, C., Dennert, G., Zwahlen, M., Brinkman, M., Zeegers, M. P., Horneber, M., D'Amico, R., & Crespi, C. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005195.pub4 · Cited by 649
Reactive oxygen species in redox cancer therapy
Tong, L., Chuang, C.-C., Wu, S., & Zuo, L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.008 · Cited by 394
Environmental Selenium and Human Health: an Update
Vinceti, M., Filippini, T., & Wise, L. A. (2018) · Current Environmental Health Reports · doi:10.1007/s40572-018-0213-0 · Cited by 269
Cancer, Oxidative Stress, and Metastasis
Gill, J. G., Piskounova, E., & Morrison, S. J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030791 · Cited by 266
Selenium exposure and the risk of type 2 diabetes: A systematic review and meta-analysis
Vinceti, M., Filippini, T., & Rothman, K. J. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0422-8 · Cited by 233
Healy, C., Munoz-Wolf, N., Strydom, J., Faherty, L., Williams, N. C., Kenny, S., Donnelly, S. C., & Cloonan, S. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01722-y · Cited by 78
Metadata
- Authors
- Karp, D. D., Lee, S. J., Keller, S. M., Wright, G. S., Aisner, S., Belinsky, S. A., Johnson, D. H., Johnston, M. R., Goodman, G., Clamon, G., Okawara, G., Marks, R., Frechette, E., McCaskill-Stevens, W., Lippman, S. M., Ruckdeschel, J., & Khuri, F. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-20
- Volume
- 31
- Issue
- 33
- Pages
- 4179-4187
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2121667178
- Cited by
- 130
- References
- 7
- FWCI
- 9.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.